chemotherapy agents Flashcards
non-specific chemotherapy drug category
- nitrosource
- alkylating agents
- anthracyclines
- platinum agents
specific chemotherapy drug category
- folate antagonist
- purine antagonist
- pyrimidine analogues
- microtubule targeting agents
- topoisomerase inhibitors
folate antagonist
methotrexate
alkylating agents
- cyclophosphamide
2. ifosfamide
______ metabolite from alkylating agent can cause bladder irritation
acrolein
what is administered with alkylating agents if acrolein metabolite occurs?
mesna
is ifosfamide or cyclophosphamide more toxic when it comes to acrolein?
ifosfamide
what are toxicities of alkylating agents?
- myelosuppression
- hemorrhage cystitis- buildup of metoblites ex. acrolein
- infertility
- nausea / vomiting
- secondary malignancy
nitrosource is known as the ____ and was developed from WWII mustard gas
first chemotherapy agent
what are two drugs that are considered nitrosource chemotherapy drugs?
CARLO was a man who fought during the MUSTy WWII
- CARmustine
- LOmustine
what are the toxicities of nitrosource?
- nausea and vomiting
- myelosuppression
- phlebitis
- pulmonary issues
what are the the three drugs listed as anthracyclines?
anthracycylines are a CYCLE of RUBs to kill of that cancer “rubicin”
- doxorubicin
- daunorubicin
- idarubicin
what major side effects do anthracyclines cause?
- dose dependent biventricular heart failure
2. extraversion rash and blisters if the IV is not paced in the vein and anthracycline spills into the peripheral tissue
What are three platinum agents?
“platin”
- cisplatin
- carboplatin
- oxliplatin
cisplatin side effect
nausea and vomiting
nephrotoxic
carboplatin side effect
thrombocytopenia
oxliplatin
cold sensitivity, peripheral neuropathies and numbness
murine monoclonal antibodies
- onab
chimeric antibodies
- imab
humanized antibodies
- umab
human antibodes
- mumab
what is more toxic for humans humanized, human, murine, or chimeric monoclonal antibodies?
less human = worse side effects
Ipilimumab
immunotherapy agent that inhibits CTLA4 therefore preventing the inhibition of T cells in cancer patients
Imatinib
tyrosine kinase inhibitor stops the ATP from binding and phosphorylating